AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30725192 — intervention group
Group type: COMPARATOR
Intervention: LHB tenotomy
Number of subjects: 20
Study 30725192 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 20
Study 30663967 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated mechanical peripheral stimulation (AMPS)
Number of subjects: 33
Study 30663967 — intervention group
Group type: COMPARATOR
Intervention: AMPS SHAM (placebo)
Number of subjects: 33
Study 27260638 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 54
Study 27260638 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 54
Study 24336297 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (2.5 mg, three injections in monthly intervals)
Number of subjects: 30
Study 24336297 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone (8 mg, single injection followed by two sham interventions)
Number of subjects: 30
Study 22314524 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil 600 mg q12h
Number of subjects: 797
Study 22314524 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin 1 g plus Aztreonam 1 g (V/A) q12h
Number of subjects: 797
Study 22314524 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil
Number of subjects: 797
Study 20225989 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoprophylaxis during labor
Number of subjects: 857
Study 17987533 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence cystoscopy using hexaminolevulinate (HAL, Hexvix)
Number of subjects: 0
Study 17987533 — intervention group
Group type: COMPARATOR
Intervention: Standard cystoscopy
Number of subjects: 0
Study 17987533 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence cystoscopy
Number of subjects: 0
Study 17987533 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy of bladder cancer
Number of subjects: 0
Study 15714287 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral leg strength training programme (6 weeks, three times per week)
Number of subjects: 33
Study 12173299 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis A vaccine
Number of subjects: 40
Study 12173299 — intervention group
Group type: COMPARATOR
Intervention: Diphtheria toxoid vaccine
Number of subjects: 40
Study 12173299 — intervention group
Group type: COMPARATOR
Intervention: Pneumococcal polysaccharide vaccine
Number of subjects: 40
Study 12173299 — intervention group
Group type: EXPERIMENTAL
Intervention: Proliferative response to KLH and SWM
Number of subjects: 40
Study 12173299 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-gamma and interleukin-13 release
Number of subjects: 40
Study 12173299 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigen-presenting cell-T-cell interaction
Number of subjects: 40
Study 12173299 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster immunization
Number of subjects: 40
Study 10463407 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification with continuous curvilinear capsulorhexis (group I)
Number of subjects: 35
Study 10463407 — intervention group
Group type: COMPARATOR
Intervention: Extracapsular cataract extraction with linear capsulotomy (group II)
Number of subjects: 35
Study 8747154 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech-evoked FFRs from high- and low-probability words
Number of subjects: 80
Study 8747154 — intervention group
Group type: EXPERIMENTAL
Intervention: Category cues with word stimuli
Number of subjects: 80
Study 2651744 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional formula providing 20% protein, 30% fat, and 50% carbohydrate, 1 Kcal/ml, 400 ml/day for 13 weeks
Number of subjects: 28
Study 2651744 — intervention group
Group type: COMPARATOR
Intervention: Reference product of the same consistency and taste containing 0.1 Kcal/ml, 400 ml/day for 13 weeks
Number of subjects: 28
Study 2651744 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional formula
Number of subjects: 28
Study 2651744 — intervention group
Group type: COMPARATOR
Intervention: Reference product
Number of subjects: 28
Study 1176233 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing dose (N = 12)
Number of subjects: 24
Study 1176233 — intervention group
Group type: COMPARATOR
Intervention: Continued methadone maintenance (N = 12)
Number of subjects: 24
Study 29952075 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ photo‐immunotherapy (ISPI) with 808 nm laser irradiation
Number of subjects: 70
Study 29952075 — intervention group
Group type: COMPARATOR
Intervention: Topical imiquimod alone
Number of subjects: 70
Study 28068786 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid 20 mg/kg after sternotomy and 20 mg/kg after heparin reversal (Group A)
Number of subjects: 75
Study 28068786 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapericardial tranexamic acid 50 mg/kg in 20 mL of saline before sternal closure (Group B)
Number of subjects: 75
Study 28068786 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of intravenous tranexamic acid 20 mg/kg after sternotomy and intrapericardial tranexamic acid 50 mg/kg before sternal closure (Group C)
Number of subjects: 75
Study 25700103 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent Training (CT)
Number of subjects: 25
Study 25700103 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Concurrent Training (BFR-CT)
Number of subjects: 25
Study 25700103 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 25
Study 23483571 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg carvedilol tablets
Number of subjects: 34
Study 21857020 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular (BIV) pacing
Number of subjects: 50
Study 21857020 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular (RV) pacing
Number of subjects: 50
Study 19453736 — intervention group
Group type: EXPERIMENTAL
Intervention: Emollient used as maintenance therapy after topical corticotherapy
Number of subjects: 0
Study 19453736 — intervention group
Group type: COMPARATOR
Intervention: Topical corticosteroid therapy
Number of subjects: 0
Study 17101936 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 18411
Study 17101936 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 18411
Study 17101936 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 18411
Study 17101936 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril vs Chlorthalidone
Number of subjects: 18411
Study 17101936 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine vs Chlorthalidone
Number of subjects: 18411
Study 15610929 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 384
Study 12352270 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 132
Study 12352270 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 40 mg alone (medication management)
Number of subjects: 132
Study 9924849 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (target dose 25 mg twice daily)
Number of subjects: 415
Study 9924849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 415
Study 7636712 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper mid-arm circumference
Number of subjects: 37
Study 7636712 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age
Number of subjects: 37
Study 7636712 — intervention group
Group type: EXPERIMENTAL
Intervention: Tape measure nomogram
Number of subjects: 37
Study 7636712 — intervention group
Group type: EXPERIMENTAL
Intervention: Guessing
Number of subjects: 37
Study 2616824 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg salbutamol via Rotacaps
Number of subjects: 18
Study 2616824 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg salbutamol via Rotacaps
Number of subjects: 18
Study 2616824 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg salbutamol via Rotacaps
Number of subjects: 18
Study 2616824 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg salbutamol via nebulizer
Number of subjects: 18
Study 2616824 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg salbutamol via nebulizer
Number of subjects: 18
Study 2616824 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg salbutamol via nebulizer
Number of subjects: 18
Study 326295 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone valerate aerosol (800 microgram per day)
Number of subjects: 23
Study 326295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 30879186 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint interval training (SITG)
Number of subjects: 30
Study 30879186 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent training (CTG)
Number of subjects: 30
Study 30879186 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RTG)
Number of subjects: 30
Study 30879186 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions (RTG, SITG, CTG)
Number of subjects: 30
Study 30879186 — intervention group
Group type: COMPARATOR
Intervention: Control group (CONG)
Number of subjects: 30
Study 28650683 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP)
Number of subjects: 102
Study 28650683 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mechanical bowel preparation)
Number of subjects: 102
Study 25552372 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced glycogen (RED)
Number of subjects: 12
Study 23715097 — intervention group
Group type: EXPERIMENTAL
Intervention: Right primary auditory cortex to right superior temporal gyrus (feed-forward) connection modulation
Number of subjects: 0
Study 23715097 — intervention group
Group type: EXPERIMENTAL
Intervention: Left primary auditory cortex to right primary auditory cortex (interhemispheric) connection modulation
Number of subjects: 0
Study 23715097 — intervention group
Group type: EXPERIMENTAL
Intervention: Left superior temporal gyrus to right superior temporal gyrus connection
Number of subjects: 0
Study 23715097 — intervention group
Group type: EXPERIMENTAL
Intervention: Right superior temporal gyrus to right primary auditory cortex connection
Number of subjects: 0
Study 23715097 — intervention group
Group type: COMPARATOR
Intervention: Self-connections in left primary auditory cortex and bilateral superior temporal gyrus
Number of subjects: 0
Study 21849054 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP)
Number of subjects: 268
Study 21849054 — intervention group
Group type: COMPARATOR
Intervention: Supportive psychotherapy
Number of subjects: 268
Study 19101251 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive virtual patient (VP) interaction
Number of subjects: 21
Study 19101251 — intervention group
Group type: COMPARATOR
Intervention: No VP interaction (control)
Number of subjects: 21
Study 17353778 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA
Number of subjects: 216
Study 17353778 — intervention group
Group type: COMPARATOR
Intervention: Aza
Number of subjects: 216
Study 14756852 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan formulations (various routes of administration)
Number of subjects: 0
Study 14756852 — intervention group
Group type: COMPARATOR
Intervention: Placebo formulations (matching sumatriptan formulations)
Number of subjects: 0
Study 11445210 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: One Step applied with the small brush provided by the manufacturer and LC (Light‐cured before resin cement application)+Dual Link resin cement
Number of subjects: 40
Study 11445210 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: One Step applied with a thin microbrush LC+Dual Link resin cement
Number of subjects: 40
Study 11445210 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: One Step applied with a small brush (Not light‐cured)+Dual Link resin cement
Number of subjects: 40
Study 11445210 — intervention group
Group type: COMPARATOR
Intervention: Group 4: All Bond 2+C & B resin cement (as control)
Number of subjects: 40
Study 9692690 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium alginate (4 sachets per day)
Number of subjects: 353
Study 9692690 — intervention group
Group type: COMPARATOR
Intervention: Cisapride (5 mg four times a day)
Number of subjects: 353
Study 8154506 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Number of subjects: 16
Study 8154506 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (mean dose: 248 mg)
Number of subjects: 16
Study 31826802 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel micellar (250 mg/m2, 1-h infusion) + carboplatin (AUC 5-6)
Number of subjects: 789
Study 31826802 — intervention group
Group type: COMPARATOR
Intervention: Cr-EL paclitaxel (175 mg/m2, 3-h infusion) + carboplatin (AUC 5-6)
Number of subjects: 789
Study 31826802 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel micellar
Number of subjects: 789
Study 31826802 — intervention group
Group type: COMPARATOR
Intervention: Cr-EL paclitaxel
Number of subjects: 789
Study 30895326 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted locomotor training for 60 days
Number of subjects: 24
Study 30895326 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 24
Study 29077818 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPP (Recovery Assessment by Phone Points)
Number of subjects: 997
Study 29077818 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 997
Study 25455873 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (8.5-mL dose administered to the portio, cervix, and uterus)
Number of subjects: 218
Study 25455873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study 24064189 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative writing condition (writing about a bad drinking experience)
Number of subjects: 200
Study 24064189 — intervention group
Group type: COMPARATOR
Intervention: Positive writing condition (writing about a good drinking experience)
Number of subjects: 200
Study 24064189 — intervention group
Group type: COMPARATOR
Intervention: Neutral writing condition (writing about the first day of college)
Number of subjects: 200
Study 21876297 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) treatment with continuous wave of 1.5w/cm² for 10 minutes before stretching
Number of subjects: 0
Study 21876297 — intervention group
Group type: COMPARATOR
Intervention: Passive stretching exercise
Number of subjects: 0
Study 18535611 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaxial phacoemulsification (CP)
Number of subjects: 64
Study 18535611 — intervention group
Group type: EXPERIMENTAL
Intervention: Biaxial phacoemulsification (MICS)
Number of subjects: 64
Study 18535611 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 64
Study 16802486 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% (n=16)
Number of subjects: 48
Study 16802486 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% (n=16)
Number of subjects: 48
Study 16802486 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% (n=16)
Number of subjects: 48
Study 12492743 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (vitamins A, C and E, selenium, methionine and ubiquinone) for 12 weeks
Number of subjects: 61
Study 12492743 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 61
Study 12492743 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation
Number of subjects: 61
Study 12492743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 10688560 — intervention group
Group type: EXPERIMENTAL
Intervention: Open access follow up
Number of subjects: 180
Study 10688560 — intervention group
Group type: COMPARATOR
Intervention: Routine booked appointments
Number of subjects: 180
Study 9085313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime 200 mg
Number of subjects: 10
Study 9085313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime 500 mg
Number of subjects: 10
Study 9085313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil 500 mg
Number of subjects: 10
Study 9085313 — intervention group
Group type: EXPERIMENTAL
Intervention: Loracarbef 400 mg
Number of subjects: 10
Study 9085313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor 500 mg
Number of subjects: 10
Study 8105525 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinary least squares (OLS) estimates
Number of subjects: 0
Study 8105525 — intervention group
Group type: EXPERIMENTAL
Intervention: Transformed data using OLS
Number of subjects: 0
Study 8105525 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational study and clinical trial data
Number of subjects: 0
Study 3545103 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketanserin
Number of subjects: 15
Study 3545103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31907026 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hydroxybenzylamine acetate (500 or 750 mg) administered every eight hours for two weeks
Number of subjects: 0
Study 31907026 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hydroxybenzylamine acetate (500 or 750 mg)
Number of subjects: 0
Study 29885994 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (5 mg/kg intravenously every 2 weeks for 4 cycles)
Number of subjects: 112
Study 29885994 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids (methylprednisolone 500 mg/day intravenously for 3 days, then tapered, followed by 10 mg/day oral prednisone for 2 months)
Number of subjects: 112
Study 26420905 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) focused on cognitive functioning
Number of subjects: 64
Study 26420905 — intervention group
Group type: COMPARATOR
Intervention: Sham control interview focused on assessment and feedback about preferred learning styles
Number of subjects: 64
Study 24131197 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine application
Number of subjects: 140
Study 24131197 — intervention group
Group type: COMPARATOR
Intervention: Dry cord care
Number of subjects: 140
Study 23106916 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Care Planning (MCP)
Number of subjects: 154
Study 23106916 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 154
Study 20390619 — intervention group
Group type: EXPERIMENTAL
Intervention: Starved (sitcom depicting individuals with eating disorders)
Number of subjects: 0
Study 20390619 — intervention group
Group type: COMPARATOR
Intervention: The Comeback (sitcom unrelated to eating disorders)
Number of subjects: 0
Study 18524413 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-lunch condition
Number of subjects: 30
Study 18524413 — intervention group
Group type: COMPARATOR
Intervention: Post-lunch condition
Number of subjects: 30
Study 18524413 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotic Listening Task (DLT)
Number of subjects: 30
Study 16243240 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID administered 1 hour postoperatively
Number of subjects: 80
Study 16243240 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID administered 1 hour preoperatively
Number of subjects: 80
Study 16243240 — intervention group
Group type: EXPERIMENTAL
Intervention: No scheduled administration pre- or postsurgery
Number of subjects: 80
Study 16243240 — intervention group
Group type: COMPARATOR
Intervention: All groups (preemptive, posttreatment, no-treatment)
Number of subjects: 80
Study 12363161 — intervention group
Group type: EXPERIMENTAL
Intervention: Winnie technique
Number of subjects: 69
Study 12363161 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial technique
Number of subjects: 69
Study 12363161 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined technique
Number of subjects: 69
Study 10201663 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (25 microg x kg(‐1) x min(‐1))
Number of subjects: 32
Study 10201663 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil (0.02 microg x kg(‐1) x min(‐1))
Number of subjects: 32
Study 10201663 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 32
Study 10201663 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 32
Study 7598681 — intervention group
Group type: EXPERIMENTAL
Intervention: Worrying about a stressor for a period of 4 minutes after exposure
Number of subjects: 0
Study 7598681 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging about the stressor
Number of subjects: 0
Study 7598681 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 0
Study 7598681 — intervention group
Group type: EXPERIMENTAL
Intervention: Worrying about usual concerns
Number of subjects: 0
Study 7598681 — intervention group
Group type: COMPARATOR
Intervention: Settle-down control condition
Number of subjects: 0
Study 2185965 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% fenticonazole spray
Number of subjects: 100
Study 2185965 — intervention group
Group type: COMPARATOR
Intervention: 1% cyclopyroxolamine spray
Number of subjects: 100
Study 392622 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin F2 alpha
Number of subjects: 140
Study 392622 — intervention group
Group type: COMPARATOR
Intervention: Ergometrin
Number of subjects: 140
Study 392622 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 140
Study 30148437 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (subcutaneous)
Number of subjects: 99
Study 30148437 — intervention group
Group type: COMPARATOR
Intervention: TNFi (infliximab)
Number of subjects: 99
Study 30148437 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (after switching from TNFi)
Number of subjects: 99
Study 30148437 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (for ANA/anti-dsDNA autoantibody-positive patients)
Number of subjects: 99
Study 29244743 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g of creatine nitrate (CNH)
Number of subjects: 28
Study 29244743 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g of creatine nitrate (CNL)
Number of subjects: 28
Study 29244743 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 28
Study 26617438 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiao-Ai-Tong (XAT) 200 mL, bid, for 7 consecutive days
Number of subjects: 0